Chemo-Pharma Laboratories Information
Contact top employees from
Chemo-Pharma Laboratories
Summary
Chemo-Pharma Laboratories is a private company. The company currently specializes in the Pharmaceuticals area. The Chemo-Pharma Laboratories annual revenue is estimated at < 1M. To connect with Chemo-Pharma Laboratories employee register on SignalHire.
Organization Website | chemopharmalabs.com |
Industries | |
Headquarters Location | Great Clarendon Court, 13 Olanrewaju Street Oregun, Ikeja, Lagos, ikeja, NG |
Employees Size | 200-500 employees |
Specialties | Manufacturing, Quality Assurance, Pharmaceuticals |
Founded | 1985 |
Operating Status | Independent Company |
Employees Turnover 1 quarter 2026
Length of Employment
Employee tenure at Chemo-Pharma Laboratories shows a diverse range of experience levels:
19% for 1–2 years13% for 3–4 years19% for 5–7 years13% for 8–10 years38% have over 11 years of service at Chemo-Pharma LaboratoriesContact top employees from
Chemo-Pharma Laboratories
Ayotunde Adeniyi
Micriobiologist/ Quality Control specialist
OGUNDIMU FUNSHO
Admin Manager
Atobatele Emmanuel
Account Executive
Mercy Otibhor Irabornose
Regulatory Affairs Officer
Cornelius Beckley
Production Pharmacist
Companies Similar to Chemo-Pharma Laboratories
FAQ
Chemo-Pharma Laboratories operates in the Pharma industries. More details can be found on the official website: chemopharmalabs.com.
The headquarters of Chemo-Pharma Laboratories are located in ikeja, Nigeria.
Chemo-Pharma Laboratories currently employs 200-500 people.
Chemo-Pharma Laboratories's revenue is approximately < 1M.
Data Privacy
GDPR COMPLIANT
SignalHire complies with the General Data Protection Regulation (GDPR). SignalHire follows GDPR requirements, including but not limited to rights of data subjects to access, correct, or delete their personal information and supports the right to be forgotten.
CCPA COMPLIANT
SignalHire is CCPA-compliant and provides California residents the right to know, access, opt out, and request deletion of their personal data.
